

REGISTERED NUMBER: 08887268 (England and Wales)

ONCOCIDIA LIMITED

**PREVIOUSLY KNOWN AS
EFUN DATA LIMITED**

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2016

**ONCOCIDIA LIMITED (REGISTERED NUMBER: 08887268)
PREVIOUSLY KNOWN AS EFUN DATA LIMITED**

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2016**

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

**ONCOCIDIA LIMITED
PREVIOUSLY KNOWN AS EFUN DATA LIMITED**

**COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2016**

DIRECTORS:

Professor Y Ni
D Davies
C Jonscher

SECRETARY:

J D B Martin

REGISTERED OFFICE:

C/O Wilkins Kennedy LLP
Anglo House
Bell Lane Office Village, Bell Lane
Amersham
Buckinghamshire
HP6 6FA

REGISTERED NUMBER:

08887268 (England and Wales)

**ONCOCIDIA LIMITED (REGISTERED NUMBER: 08887268)
PREVIOUSLY KNOWN AS EFUN DATA LIMITED**

**BALANCE SHEET
31 DECEMBER 2016**

	Notes	2016 £	2015 £
CURRENT ASSETS			
Debtors	5	201	-
Cash at bank and in hand		125,574	1
		<u>125,775</u>	<u>1</u>
CREDITORS			
Amounts falling due within one year	6	(8,951)	-
NET CURRENT ASSETS		<u>116,824</u>	<u>1</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>116,824</u>	<u>1</u>
CAPITAL AND RESERVES			
Called up share capital		545	1
Share premium		125,230	-
Retained earnings		(8,951)	-
SHAREHOLDERS' FUNDS		<u>116,824</u>	<u>1</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2016.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2016 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
- (b)

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 26 September 2017 and were signed on its behalf by:

D Davies - Director

The notes form part of these financial statements

**ONCOCIDIA LIMITED (REGISTERED NUMBER: 08887268)
PREVIOUSLY KNOWN AS EFUN DATA LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2016**

1. STATUTORY INFORMATION

OncoCiDia Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements have been prepared under the historical cost convention.

These financial statements for the year ended 31 December 2016 are the first financial statements that comply with FRS 102 including Section 1A. The company transitioned from previously extant UK GAAP to FRS 102 as at 1 March 2015. An explanation of how transition to FRS 102 has affected the reported financial position and financial performance is given in a note to the accounts.

The financial statements are presented in sterling (£), which is also the functional currency for the company.

Significant judgements and estimates

The preparation of financial statements requires management to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on a continuing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Financial reporting standard 102 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows;

**ONCOCIDIA LIMITED (REGISTERED NUMBER: 08887268)
PREVIOUSLY KNOWN AS EFUN DATA LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2016**

3. ACCOUNTING POLICIES - continued

Debtors

Other debtors are measured at transaction price less any impairment unless the arrangement constitutes a financing transaction in which case the transaction is measured at the present value of the future receipts discounted at the prevailing market rate of interest. Loans are initially measured at fair value and are subsequently measured at amortised cost using the effective interest method less any impairment.

Cash at bank and in hand

Cash at bank and in hand in the balance sheet comprise cash at bank and in hand and short term deposits with an original maturity date of three months or less.

Creditors

Other creditors are measured at their transaction price unless the arrangement constitutes a financing transaction in which case the transaction is measured at the present value of future payments discounted at the prevailing market rate of interest. Other financial liabilities are initially measured at fair value net of their transaction costs. They are subsequently measured at amortised cost using the effective interest method.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2015 - 1) .

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2016 £	2015 £
Other debtors	<u>201</u>	<u>-</u>

ONCOCIDIA LIMITED (REGISTERED NUMBER: 08887268)
PREVIOUSLY KNOWN AS EFUN DATA LIMITED

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2016

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2016	2015
	£	£
Amounts owed to associates	8,101	-
Other creditors	850	-
	<u>8,951</u>	<u>-</u>

7. RELATED PARTY DISCLOSURES

Included in creditors: amounts falling due within one year is £7,861 (2015: £nil) due to Frontier Biosciences Limited and £240 (2015: £nil) due to CetroMed Limited, both associated companies.

8. ULTIMATE CONTROLLING PARTY

There is no ultimate controlling party.

9. FIRST YEAR ADOPTION

The company has adopted FRS 102 for the first time in the year ended 31 December 2016. The policies applied under the entity's previous accounting framework are not materially different to FRS 102 and have not impacted on the comparative period figures.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.